Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 6 of 41
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
NCT05180591
Ruxolitinib in Thrombocythemia and Polycythemia Vera
NCT04644211
The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU
NCT04737200
NTS-WBRT in Brain Metastases
NCT05013892
Intermittent Fasting for NAFLD in Adults
NCT04899102
An Ethical Approach to Detecting Covert Consciousness
NCT05010265
Cannabidiol for Reduction of Brain Neuroinflammation
NCT05066308
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
NCT05157880
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
NCT04833140
Promoting Well-being and Health in Heart Failure
NCT04829617
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
NCT04945707
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
NCT04842266
The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease
NCT04505865
Oxytocin for Weight Loss in Adolescents
NCT04551482
The Role of Wearable Devices in Cardiothoracic Surgery: Predicting and Detecting Early Postoperative Complications
NCT04824066
Folfox+Irinotecan+Chemort In Esophageal Cancer
NCT04656041
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Phenotyping Asthma for Bronchial Thermoplasty
NCT03435237
Computational Neuroscience of Language Processing in the Human Brain
NCT05222594
ACP Video Intervention for Patients With Life-Limiting Illness
NCT04778761
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
NCT04699747
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Personalized Performance Optimization Platform
NCT06979570
Epidermal Skin Grafts to Improve Healing In Radiation Wounds
NCT04560803
Sleep Spindles and Memory in Rolandic Epilepsy
NCT04569708
Extracellular RNA Biomarkers of Myotonic Dystrophy
NCT05020002
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
NCT04560322
Thoracoabdominal Asynchrony and Respiratory Distress
NCT04626154
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NCT05577819
Cortical-Basal Ganglia Speech Networks
NCT04286308
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
NCT04508088
Decompression Versus Decompression and Fusion
NCT04542720
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
NCT04400266
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT04485286
Sacituzumab Govitecan In TNBC
NCT04230109
The HALT Biomarker Study
NCT04552275
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03803553
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT04794322
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
NCT03748446
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
NCT05016908
Effect of Theophylline in Pseudohypoparathyroidism
NCT03718403
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
NCT03909139
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03922555
VE416 for Treatment of Food Allergy
NCT03936998
The Role of Estrogen in the Neurobiology of Eating Disorders
NCT03740204
EVOC - EVs in Obesity and Cardiometabolic Disease
NCT06408961
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
NCT03531450
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
NCT03603730
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.